期刊文献+

中国骨科手术加速康复——围术期血液管理专家共识 被引量:96

Expert consensus in enhanced recovery after orthopedic surgery in China:perioperative blood management
暂未订购
导出
摘要 骨科手术出血量大、异体输血率高,骨科手术患者术前及术后贫血的发生率高。围术期贫血增加术后感染风险,延长住院时间,影响术后功能康复和生活质量;异体输血存在输血相关不良反应风险,增加血液资源紧张局面及患者医疗负担。因此,加强骨科大手术围术期血液管理(perioperative blood management,PBM)是实施加速康复的重要环节。通过查阅文献,基于国家卫生计生委公益性行业科研专项《关节置换术安全性与效果评价》项目组数据库大样本数据分析,遵循循证医学原则,经过全国专家组反复讨论,针对临床骨科大手术患者围术期血液管理达成共识,供广大骨科医师在临床工作中参考应用。围术期血液管理是指在围术期的各个阶段采取多种技术进行血液质和量的保护,以减少失血、降低贫血及输血率,提高手术安全性和医疗质量,增加患者满意度。其主要内容包括:术前术后优化造血、术中减少出血、提高患者贫血耐受性及合理异体输血。 Patients with orthopeadic surgery usually suffer from large blood loss and high incidence of transfusion and preoperative and postoperative anemia. Perioperative anemia will increase the rate of infection, prolong the length of hospital stay, and affect function recovery and life quality. Allogeneic transfusion will increase the incidence of complications related to transfusion, the tension of blood resource and medical burden. Therefore, perioperative blood management(PBM) of orthopedic surgery is an important step in enhanced recovery after surgery(ERAS). Based on literatures and expert group discussion combined with the database of the project group for the "National Health and Family Planning Commission's publicbenefit project: the safety and effect assessment of joint arthroplasty" and evidence-based medicine, we compile this consensus which mainly contains perioperative optimization of hematopoiesis, decrease of blood loss, improvement of tolerance of patients with anemia and reasonable allogeneic transfusion. We aim to decrease the blood loss and incidence of anemia and transfusion, improve the safety of surgery and medical quality and patients' satisfaction through PBM in the perioperative period of orthopedic surgery. Also, we hope that this consensus would give some help to orthopedic surgeons.
出处 《中国骨与关节外科》 2017年第1期1-7,共7页 Chinese Journal of Bone and Joint Surgery
关键词 骨科手术 血液管理 加速康复 围手术期医护 Orthopedics Surgey Blood Management Enhanced Recovery After Surgery(ERAS) Perioperative Care
  • 相关文献

参考文献7

二级参考文献51

  • 1魏志武,李锋春.对2286例患者输血前4项检验结果的流行病学研究[J].职业与健康,2004,20(7):63-65. 被引量:12
  • 2National Comprehensive Cancer Network. NCCN clinical practiceguidelines in oncology: cancer and chemotherapy-induced anemia.2011, V. 2 [EB/OL]. (2011-08-01). http://www. nccn. org/index. asp.
  • 3Del Mastro L, Gennari A, Donati S. Chemotherapy of non-small-celllung cancer: role of erythropoietin in the management of anemia[J].Ann Oncol, 1999,10 (Suppl 5): 91-94.
  • 4Ludwig H, Van Belle S, Barrett-Lee P, et al. The European CancerAnaemia Survey (ECAS): A large, multinational, prospective surveydefining the prevalence; incidence, and treatment of anaemia in cancerpatients [J]. EurJ Cancer, 2004,40: 2293-2306.
  • 5Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietinresponse in patients with the anemia of cancer[j]. N EngJ Med, 1990,322: 1689-1692.
  • 6Hockel M, Vaupel P. Tumor hypoxia: Definitions and current clinical,biologic, and molecular aspects[J].J Natl Cancer Inst, 2001, 93: 266-276.
  • 7Ludwig H, Fritz E. Anemia in cancer patients [J]. Semin Oncol,1998,25 (3 Suppl 7):2-6.
  • 8Leyland-Jones B, Semiglazov V,Pawlicki M, et al. Maintaining normalhemoglobin levels with epoetin alfa in mainly nonanemic patients withmetastatic breast cancer receiving first-line chemotherapy: A survivalstudy[J].J Clin Oncol, 2005,23(25): 5960-5972.
  • 9Bohlius J, Schmidlin K, Brillant C, et al. Recombinant humanerythropoiesis-stimulating agents and mortality in patients with cancer:a meta-analysis of randomised trials [J]. Lancet, 2009,373: 1532-1542.
  • 10Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individualpatient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin-alfa in the treatment of patients withchemotherapy-induced anemia[J].J Clin Oncol, 2009, 27:2838-2847.

共引文献495

同被引文献690

引证文献96

二级引证文献725

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部